Efficacy and outcomes of bempedoic acid versus placebo in patients with hypercholesterolemia: An updated systematic review and meta-analysis of randomized controlled trials
Document Type
Review Article
Department
Internal Medicine
Abstract
Introduction: Bempedoic acid (BA) has shown varied efficacy in managing hyperlipidemia. We conducted the most extensive up-to-date meta-analysis, the first to include recent studies by Nissen et al., which boast the largest sample size.
Methods: Literature search was done on Medline, EMBASE, and Cochrane Library. The primary endpoint was a change in low-density lipoprotein-cholesterol (LDL-C) levels, while secondary endpoints encompassed changes in lipid parameters, clinical endpoints, and safety endpoints. The least-square mean (LSM) percent change was utilized for lipid changes, with statistical significance set at P < 0.05.
Results: This analysis included 12 randomized control trials with 22,249 participants. BA exhibited a substantial reduction in LDL-C levels [LSM % change, -24.34; 95% confidence interval (CI), -27.80 to -20.88; P < 0.0001], total cholesterol levels (LSM % change, -16.62; 95% CI, -21.70 to -11.54; P < 0.00001) and high-density lipoprotein-cholesterol (HDL-C) levels (LSM % change, -4.22; 95% CI, -5.51 to -2.92; P < 0.00001) compared to the placebo.
Conclusions: BA significantly lowers LDL-C, total cholesterol, HDL-C, non-HDL-C, high sensitivity C reactive protein, and apolipoprotein levels.
Publication (Name of Journal)
Cardiovascular Endocrinology & Metabolism
DOI
10.1097/XCE.0000000000000302
Recommended Citation
Goyal, A.,
Shah, S.,
Dahal, K.,
Changez, M. K.,
Tariq, M. D.,
Zuhair, V.,
Shamim, U.,
Abbasi, H. Q.,
Shrestha, A. B.,
Sah, R.
(2024). Efficacy and outcomes of bempedoic acid versus placebo in patients with hypercholesterolemia: An updated systematic review and meta-analysis of randomized controlled trials. Cardiovascular Endocrinology & Metabolism, 13(3), e0302.
Available at:
https://ecommons.aku.edu/pakistan_fhs_mc_med_intern_med/266